Cockett A T, de Sant'agnese P A, Hamlin D J, Keys H M
Urology. 1982 Jun;19(6):593-8. doi: 10.1016/0090-4295(82)90006-1.
Thirty-four patients wih infiltrative bladder carcinoma, Stage B2C or higher were treated with immunotherapy and irradiation. Seventeen patients are alive, and 17 have succumbed to their disease. Eight patients underwent cystectomy after immunotherapy and irradiation; 6 of 8 are alive and well at the present time. The technique of immunotherapy is outlined. New methodology for sequential CT scans and scheduled bladder biopsies is mentioned. The 17 patients have survived twelve to sixty-nine months after immunotherapy and irradiation. Downstaging is demonstrated based on sequential CT scans of the bony pelvis and histologic biopsy. The biopsies reveal eosinophilia and multinucleated giant cells, a specific response to immunotherapy. A prospective randomized study will be initiated.
34例浸润性膀胱癌患者(B2C期或更高分期)接受了免疫治疗和放疗。17例患者存活,17例患者死于该病。8例患者在免疫治疗和放疗后接受了膀胱切除术;8例中有6例目前存活且状况良好。文中概述了免疫治疗技术。提到了连续CT扫描和定期膀胱活检的新方法。17例患者在免疫治疗和放疗后存活了12至69个月。基于骨盆的连续CT扫描和组织活检显示了分期降低。活检显示嗜酸性粒细胞增多和多核巨细胞,这是对免疫治疗的特异性反应。将启动一项前瞻性随机研究。